The American College of Medical Genetics and Genomics (ACMG) has published a new statement, Points to Consider for the Reporting of Variants of Uncertain Significance in Germline Genetic and Genomic ...
GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact GeneDx (Nasdaq: WGS), ...
In a major step toward expanding patient access, MyOme is highlighting its strategic partnership with Natera (NASDAQ: NTRA) to launch Zenith™ powered by MyOme. Zenith is a premium exome and genome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
